Navitoclax + Venetoclax
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelofibrosis
Conditions
Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma
Trial Timeline
— → —
NCT ID
NCT03592576About Navitoclax + Venetoclax
Navitoclax + Venetoclax is a pre-clinical stage product being developed by AbbVie for Myelofibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03592576. Target conditions include Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03592576 | Pre-clinical | Completed |
Competing Products
20 competing products in Myelofibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| Nusivertib + Ruxolitinib + Momelotinib | Sumitomo Pharma | Phase 1/2 | 41 |
| Ruxolitinib + Navitoclax | AbbVie | Phase 2 | 52 |
| ABBV-744 + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Placebo for Navitoclax + Ruxolitinib + Navitoclax | AbbVie | Phase 3 | 77 |
| Mivebresib + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Navitoclax + Ruxolitinib + Best Available Therapy (BAT) | AbbVie | Phase 3 | 77 |
| NS-018 + Best Available Therapy | Nippon Shinyaku | Phase 2 | 52 |
| AZD1480 | AstraZeneca | Phase 1 | 33 |
| Bomedemstat | Merck | Phase 2 | 52 |
| Peginterferon alfa-2a | Merck | Phase 2 | 52 |
| Bomedemstat | Merck | Phase 1/2 | 41 |
| MBG453 + NIS793 + Spartalizumab + Decitabine | Novartis | Phase 1 | 33 |
| PIM447 + Ruxolitinib + LEE011 | Novartis | Phase 1 | 33 |
| LDE225 + INC424 | Novartis | Phase 1/2 | 41 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793 | Novartis | Phase 1/2 | 41 |
| Ruxolitinib + Ruxolitinib Placebo | Novartis | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |
| ruxolitinib | Novartis | Phase 2 | 52 |